Outlook Therapeutics grants CFO 500,000 options

The CFO of Outlook Therapeutics received 500,000 inducement stock options at a $0.63 exercise price with long-term vesting.

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. (OTLK) reported that its Chief Financial Officer, Kevin Michael Lundquist, received a grant of 500,000 employee stock options on September 1, 2026. The options have an exercise price of $0.63 per share and expire on September 1, 2036. The grant was made as an inducement to his employment under Nasdaq Listing Rule 5635(c)(4) and vests 25% on September 1, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to his continuous service.

Insider Trade Summary

Grant/Award: 500,000 shares

Grant/Award 1 txn

Insider Lundquist Kevin Michael

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F1	500,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 500,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted by Outlook Therapeutics, Inc. (the "Issuer") as an inducement material to the Reporting Person's entry into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). 25% of the shares subject to the option shall vest on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.

Key Figures

Employee stock options granted: 500,000 options Exercise price: $0.63 per share Expiration date: September 1, 2036 +2 more

5 metrics

Employee stock options granted 500,000 options Grant to CFO on September 1, 2026

Exercise price $0.63 per share Exercise price of the CFO’s employee stock option grant

Expiration date September 1, 2036 Expiration of the CFO’s granted options

Vesting cliff 25% on September 1, 2027 Initial vesting of the option grant subject to continuous service

Underlying common shares 500,000 shares Common Stock underlying the granted employee stock options

Key Terms

Employee Stock Option, Nasdaq Listing Rule 5635(c)(4), inducement, vesting

4 terms

Employee Stock Option financial

"The reporting person received an Employee Stock Option (Right to Buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

Nasdaq Listing Rule 5635(c)(4) regulatory

"granted as an inducement material to the Reporting Person's entry into employment"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement financial

"The option was granted ... as an inducement material to the Reporting Person's entry into employment"

Something offered to persuade someone to act a certain way, such as a payment, gift, rebate, stock award, or other benefit intended to influence decisions. Investors care because inducements can change behavior inside or around a company—affecting costs, sales practices, or management incentives—and can create conflicts of interest or trigger regulatory review. Think of it like a coupon or bonus meant to sway a choice, which can alter expected outcomes for shareholders.

vesting financial

"25% of the shares subject to the option shall vest on September 1, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OTLK report for its CFO on this Form 4?

Outlook Therapeutics reported that its CFO, Kevin Michael Lundquist, received a grant of 500,000 employee stock options on September 1, 2026, as an inducement to his employment, with an exercise price of $0.63 per share and expiration on September 1, 2036.

What are the key terms of the 500,000 stock options granted by OTLK?

The CFO’s option grant covers 500,000 shares of Common Stock at an exercise price of $0.63 per share, expiring on September 1, 2036. It was granted as an inducement to employment under Nasdaq Listing Rule 5635(c)(4).

How do the OTLK CFO’s stock options vest?

According to the disclosure, 25% of the shares subject to the option will vest on September 1, 2027. The remaining shares will vest in equal monthly installments over the following three years, subject to the CFO’s continuous service with Outlook Therapeutics.

Is the OTLK CFO’s option grant a purchase or a compensation award?

The transaction is a grant or award of an employee stock option as compensation. The Form 4 characterizes it as a grant, award, or other acquisition, with no cash purchase reported and an initial option price of $0.00 for the grant itself.

Was the OTLK CFO’s option grant made under a Rule 10b5-1 trading plan?

The Form 4 indicates no Rule 10b5-1 plan: the document-level checkbox is not marked as an affirmative 10b5-1 plan, and the footnote describes the transaction as an inducement grant, not as trades under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:33 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lundquist Kevin Michael

(Last) (First) (Middle)

111 SOUTH WOOD AVENUE

UNIT 100

(Street)

ISELIN NEW JERSEY 08830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.63	09/01/2026		A		500,000		(1)	09/01/2036	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. The option was granted by Outlook Therapeutics, Inc. (the "Issuer") as an inducement material to the Reporting Person's entry into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). 25% of the shares subject to the option shall vest on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.

	/s/ Jennifer Couture, Attorney-in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)